EPA-1627 – Brief Assesment of Funcionality in Psycotic Patients Treated with Long-acting Injectable Antipsycotic

Abstract

Introduction

An early symptomatic response has been related with an early improvement in functionality, quality of life and subjective well-being.

The short version of the Social Functioning Scale (SFS) has been validated to get round the difficulty of lack of time in our clinical practice.

Objectives

Evaluate functionality with SFS in a sample of schizophrenic outpatients treated with long-acting injectable antipsychotics.

Methods

20 outpatients with schizophrenia according to ICD-10 criteria. These patients were in treatment with long-term antipsychotic monotherapy during the past three months. Two treatment groups were established: paliperidone palmitate treatment group and another with the other long-acting injectable antipsychotics marketed in our country (constant release risperidone, olanzapine pamoate, zuclopenthixol, fluphenazine decanoate).

The severity of the disease was assesed by the CGI-S and function was assessed using the SFS. Antipsychotic medication was computed in equivalent mg of chlorpromazine (CPZe). Socio-demographic data were also collected.

Results

Mean scores of SFS were: 25.91(SD 5.66) in paliperidone palmitate group and 27 (SD 6.78) in the other antipsycotics group. Mean score of CGIS were: 3.91 (SD 0.94) in paliperidone palmitate group and 3.33 (SD 1.41) in the other antipsycotics group. Mean score of CPZe was: 427.1 (SD 102,54) in paliperidone palmitate group and 580,59 (SD 332,54) in the other antipsycotics group.

Conclusions

We don’t find significant differences between the two groups. It should be noted observational design prevent us from make relevant inferences. It is likely that with a larger sample size these data can be modified.